BioCentury
ARTICLE | Clinical News

SA-IGIV: Began Phase II testing

March 12, 2001 8:00 AM UTC

Inhibitex Inc., Alpharetta, Ga. Product: SA- IGIV Business: Infectious diseases Therapeutic category: Bacterial infection Target: S. aureus surface antigens Description: Intravenous purified human imm...